Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)

Top News rankings and signal summaries are processed using AI and may contain errors.

1
Very Bullish +78

US FDA approves Regeneron’s gene therapy, Otarmeni for genetic hearing loss

AI-generated analysis

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals' gene therapy, Otarmeni (lunsotogene parvec-cwha), marking a significant advancement in treating genetic hearing loss. This is the first gene therapy approved under the FDA Commissioner's National Priority Voucher program and is...

Bullish Signals

  • FDA granted accelerated approval for Regeneron's Otarmeni gene therapy.
  • Otarmeni is first-in-class in vivo therapy restoring natural hearing.
  • CHORD trial: 80% achieved hearing improvements within 24 weeks.
  • All responders maintained gains through 48 weeks; 42% achieved normal hearing.
  • Regeneron offers Otarmeni free in the US for accessibility.
  • Treatment is safe for young infants via cochlear implant-like surgery.
  • Otarmeni targets ultra-rare OTOF loss affecting 50 newborns yearly.

Bearish Signals

  • Clinical approval depends on confirmatory CHORD trial showing clinical benefit.
  • Not recommended if imaging shows infeasible access to inner ear.
  • Accelerated approval based on week 24 data; long-term durability unconfirmed.
  • Only 42% of participants reached normal hearing at 48 weeks.
  • Common adverse reactions include otitis, vomiting, dizziness, and nystagmus.
  • Requires specialized surgeon experience limiting immediate accessibility to few centers.
  • Limited to patients with preserved outer hair cell function.
2
Very Bullish +85

Regeneron stock weighs Q3 growth and broader Sanofi alliance

Earnings report Licensing agreement AI-generated analysis

Regeneron Pharmaceuticals reported robust third-quarter financial results, with revenue surging 36% year-over-year to $5.1 billion. Non-GAAP diluted earnings per share climbed significantly by 70% to reach $20.07, while GAAP EPS increased 35% to $18.45. These figures highlight the company's strong operational performance and ability to...

Bullish Signals

  • Revenue grew 36% YoY to $5.1B in Q3.
  • Non-GAAP EPS jumped 70% to $20.07.
  • Sanofi alliance includes $1.0B upfront payment.
  • Partnership covers four antibodies with $7.0B milestones.
  • GAAP EPS rose 35% YoY to $18.45.
3
Very Bullish +78

Regeneron Pharmaceuticals (NASDAQ:REGN) Director Kathryn Guarini Sells ...

Analyst upgrade Dividend Earnings report AI-generated analysis

Regeneron Pharmaceuticals (NASDAQ:REGN) reported strong quarterly financial results, posting $20.07 in earnings per share which significantly topped analyst consensus estimates of $16.51. The company generated revenue of $5.12 billion for the quarter, representing a 36.3% year-over-year increase compared to the prior period. Additionally, Regeneron achieved...

Bullish Signals

  • EPS beat estimates at $20.07 vs $16.51.
  • Revenue surged 36.3% YoY to $5.12 billion.
  • Net margin reached 28.51% with ROE of 16.01%.
4
Very Bullish +85

Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter

Earnings report Guidance raised Licensing agreement AI-generated analysis

Regeneron Pharmaceuticals shares surged 13% to a 52-week high of $927.89 following a blockbuster third-quarter report where adjusted earnings per share hit $20.07, significantly beating the $16.06 consensus. Revenue climbed 36% year-over-year to $5.12 billion, driven primarily by record sales across its key franchises, including...

Bullish Signals

  • Stock surged 13% to 52-week high on EPS beat.
  • Revenue grew 36% YoY for third consecutive quarter.
  • Dupixent partnership revenue hit $2.7B, up 68%.
  • Raised 2026 gross margin guidance to ~86%.
  • Eylea HD sales offset legacy drug decline.
5
Very Bullish +85

Regeneron Reports Third Quarter 2026 Financial and Operating Results

Drug approval Earnings report Licensing agreement AI-generated analysis

Regeneron Pharmaceuticals reported robust third-quarter 2026 financial results, with total revenues surging 36% year-over-year to $5.1 billion. This growth was driven by record net sales across its core portfolio, including a 35% increase in Dupixent global sales (recorded by Sanofi), a 62% jump in EYLEA...

Bullish Signals

  • Revenue up 36% to $5.1B in Q3 2026.
  • Non-GAAP EPS surged 70% to $20.07.
  • Dupixent sales hit record $6.5 billion.
  • EYLEA HD U.S. sales grew 62% to $699M.
  • Libtayo global sales rose 51% to $550M.

Bearish Signals

  • EYLEA U.S. net sales dropped 41% to $400M amid competition.
6
Very Bullish +85

Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy

AI-generated analysis

Regeneron Pharmaceuticals has secured FDA accelerated approval for Otarmeni, an adeno-associated virus vector-based gene therapy designed to restore neurosensory function in patients with severe-to-profound sensorineural hearing loss caused by biallelic variants in the OTOF gene. The therapy, previously known as DB-OTO, is indicated for children...

Bullish Signals

  • Regeneron: FDA approved Otarmeni for severe sensorineural hearing loss.
  • CHORD trial: 80% of patients improved hearing within 24 weeks.
  • 42% achieved normal hearing; all prior responders maintained response.
  • FDA CNPV pilot enables expedited 1–2 month final reviews.
  • Otarmeni offered free in U.S. for qualifying OTOF patients.
  • Intellia: lonvo-z reduced HAE attacks by 87% vs placebo.
  • 62% of lonvo-z patients attack-free; only 11% for placebo.
  • lonvo-z showed favorable safety with no serious adverse events.

Bearish Signals

  • Accelerated approval risks withdrawal if CHOIRD confirmatory data fails.
  • Small Phase I/II CHORD sample (20 participants) limits long-term safety proof.
  • 28% cohort failure at week 48 shows variable treatment outcomes.
  • Free U.S. pricing hints at global commercial viability concerns.
  • Infusion reactions and fatigue could reduce patient adherence.
7
Bullish +75

Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

AI-generated analysis

Regeneron Pharmaceuticals reported robust financial performance for its fiscal first quarter of 2026, posting 19% revenue growth and 15% non-GAAP earnings per share growth driven by strong execution within its immunology and oncology portfolios. Dupixent remained the cornerstone of the immunology franchise, achieving 31% constant...

Bullish Signals

  • Revenue grew 19%, EPS rose 15% on strong commercial execution.
  • DUPIXENT added 31% growth as immunology foundation.
  • EYLEA HD sales increased 52% YoY amid competition.
  • Libtayo oncology sales jumped 54% globally in non-melanoma cancers.
  • Two Phase III olatorepatide programs for obesity and diabetes start later this year.
  • Cemdisiran and garetosmab regulatory decisions expected in Q4 2026 and August 2026.
  • Fianlimab + Libtayo melanoma Phase III results due Q2 2026.
  • Sanofi collaboration revenue increases Q3 2026 after mid-year balance repayment.
  • Olatorepatide + Praluent combination targets weight loss and cardiovascular risk.
  • Cemdisiran gMG quarterly dosing maintained efficacy without waning.

Bearish Signals

  • GAAP gross margin hurt by Limerick site interruption.
  • $20M inventory headwind expected in Q2 EYLEA sales.
  • EYLEA demand falls ahead of biosimilar entries.
  • FDA missed April 2026 PDUFA for second EYLEA manufacturer.
  • Otarmeni U.S. free launch foregoes short-term revenue.
  • Management open to collaboration but can build independently.
  • EYLEA HD adoption pressured by competition despite growth.
8
Bearish -65

Regeneron drops after skin cancer treatment misses late-stage trial goal

AI-generated analysis

Regeneron Pharmaceuticals (REGN) shares dropped approximately 12% in morning trade on Monday, May 18, following the announcement that a late-stage clinical trial for its experimental skin cancer treatment failed to meet its primary endpoint. The combination therapy of fianlimab and cemiplimab did not achieve statistical...

Bullish Signals

  • Median PFS ~5 months longer than Keytruda.
  • Strategic partnership with Parabilis Medicines secured.
  • Potential milestone payments up to $2.2 billion.

Bearish Signals

  • Trial failed to improve progression-free survival for advanced melanoma patients.
  • Worst-case scenario sentiment expected to worsen despite limited business impact.
  • Back-to-back pipeline misses increase pressure on 12-18 month development schedule.
  • 10+ brokerages cut price targets following disappointing trial results.
  • Shares fell 12%, risking $9 billion in market value loss.
9
Bullish +75

Only 8 biotech companies made this global responsibility index — Regeneron did - Stock Titan

AI-generated analysis

Regeneron Pharmaceuticals (NASDAQ: REGN) was named to the Dow Jones Best-in-Class World Index for Global Responsibility Leadership for the seventh consecutive year and the Dow Jones Best-in-Class North America Index on May 8, 2026. The company is one of only eight biotech firms globally and...

Bullish Signals

  • Regeneron achieved seven consecutive years on Dow Jones Best-in-Class World Index.
  • One of only four U.S. biotech firms in North America Index.
  • Novel gene therapy for congenital hearing loss offered free in U.S.
  • $300 million STEM funding pledge spanning 19 years (2017–2036).
  • Top-10% ESG rankings across S&P Global, Sustainalytics, and ISS ESG.
10
Slightly Bullish +15

Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q1 Estimates, But Stock Slips on Margin Headwinds and Manufacturing Glitch - ChartMill

AI-generated analysis

Regeneron Pharmaceuticals (NASDAQ:REGN) reported a strong first quarter that exceeded analyst expectations on both revenue and earnings, driven by robust sales of its newer products and continued collaboration revenue from Dupixent. The company posted non-GAAP earnings per share (EPS) of $9.47 for the quarter ended...

Bullish Signals

  • EPS of $9.47 beat the $9.07 estimate showing strong profitability.
  • Revenue hit $3.61 billion, up 19% year-over-year beating forecasts.
  • FDA approved Otarmeni, first gene therapy for genetic hearing loss.
  • Dupixent expanded to new indications driving growth from key product.
  • Quarterly dividend of $0.94 plus $3.0 billion share repurchase program.
  • Limerick production resumed with gross margins normalizing by Q2 end.
  • Analysts project $10.84 non-GAAP EPS and over $16B sales for 2026.
  • Strong cash flows highlighted by inclusion in high free cash flow lists.

Bearish Signals

  • Shares slipped pre-market despite earnings beat amid margin concerns.
  • Ireland facility disruption squeezes gross margins and raises write-offs.
  • GAAP gross margin contracted to 76% from 81% a year ago.
  • Full-year 2026 profit outlook revised down due to manufacturing interruption.
  • Revenue beats failed to offset lowered gross margin guidance.
  • Investors fear margin pressure continues until Ireland facility ramps up.
  • GAAP EPS declined to $6.75 from $7.27 due to IPR&D charges.
11
Slightly Bullish +25

Regeneron Profit Drops on Higher Research, Development Spending

AI-generated analysis

Regeneron Pharmaceuticals reported a decline in first-quarter net income to $727.2 million, or $6.75 per share, from $808.7 million, or $7.27 per share, in the previous year's period. This decrease was primarily attributed to increased research and development spending of $1.54 billion for the quarter,...

Bullish Signals

  • Revenue surged 19% to $3.61 billion, beating targets.
  • Earnings hit $9.47 per share vs an $8.89 estimate.
  • Dupixent sales jumped 33% to $4.9 billion.
  • Eylea HD sales rose 52% to $468 million.
  • Management raised 2026 R&D targets to $6.45-$6.68B.

Bearish Signals

  • Q1 net income fell 8% to $727.2 million.
  • R&D spending of $1.54B offset key drug sales growth.
  • Eylea standard formulation sales dropped 10% to $941M.
  • Heavy R&D pressure targets $6.45B-$6.68B for 2026.
12
Bullish +75

Here’s Why Regeneron Stock Could Deliver 60% Upside Returns - TIKR.com

AI-generated analysis

Regeneron Pharmaceuticals (REGN) is highlighted as a potential investment opportunity with significant upside, driven by the continued growth of its core Dupixent franchise and a robust pipeline. The FDA recently approved Dupixent for allergic fungal rhinosinusitis in patients aged 6 and older, marking the ninth...

Bullish Signals

  • FDA approval expands franchise to $17.8 billion.
  • Regeneron collaboration profits surged 42% year-over-year.
  • FDA accepted garetosmab BLA with August decision target.
  • Revenue projected to grow from $14.3B to $15.6B.
  • Normalized net income margins held at 34.1%.
  • Management committed over $5.9 billion to R&D.
  • Consensus includes 17 buys with $870.7 target.
  • TIKR model targets $1,226.8 by 2030.

Bearish Signals

  • Fianlimab readout critical; lack of second blockbuster limits upside.
  • Normalized EPS declined 2.9%, signaling earnings floor not growth.
13
Bullish +75

Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU

AI-generated analysis

Sanofi and Regeneron announced that their biologic medication Dupixent has received U.S. FDA approval as the first treatment specifically indicated for children under 12 years of age suffering from uncontrolled chronic spontaneous urticaria, commonly known as CSU. This regulatory milestone expands upon the existing approval...

Bullish Signals

  • FDA approved Dupixent as first biologic for children ages 2–11 with CSU.
  • This milestone expands access to a new pediatric patient population.
  • As a first-in-class, Dupixent builds competitive advantage for Regeneron and Sanofi.
  • Approval extends beyond previous age range to broaden commercial reach.

Bearish Signals

  • Exposure to competition rises as Dupixent gains pediatric approval.
  • Expanding indications requires managing additional regulatory scrutiny for kids ages 2–11.
  • No negative information regarding sales impact, pricing pressure, or patent cliffs.
14
Very Bearish -75

MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller ...

AI-generated analysis

Robbins Geller Rudman & Dowd LLP is soliciting investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to serve as lead plaintiff in a shareholder class action lawsuit captioned Cheatham v. Regeneron Pharmaceuticals, Inc. The firm invites purchasers or acquirers of common stock between August 1, 2025,...

Bearish Signals

  • Alleged false statements about Phase III Fianlimab-Libtayo Study success.
  • Preliminary statistical assumptions allegedly flawed in clinical trial.
  • Trial altered April 29, 2026; stock down >6%.
  • May 15, 2026: Trial failed primary endpoint; stock -10%.
15
Bullish +75

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

AI-generated analysis

Regeneron Pharmaceuticals (REGN) reported first-quarter 2026 adjusted earnings per share of $9.47, surpassing the Zacks Consensus Estimate of $8.52 and exceeding the prior year's $8.22. Total revenues grew 19% year over year to $3.6 billion, driven by increased sales of Eylea HD and higher Dupixent...

Bullish Signals

  • Regeneron beat Q1 2026 EPS estimate at $9.47.
  • Revenues grew 19% YoY to $3.6 billion.
  • Eylea HD US sales surged 52% to $468 million.
  • Dupixent sales rose 33% to $4.9 billion.
  • Libtayo sales jumped 54% to $438 million.
  • Gross margin improved to 86%.
  • FDA approved Dupixent for children aged 2-11.
  • Eylea HD dosing interval extended to 20 weeks.
  • Otarmeni gene therapy received accelerated FDA approval.
  • Company repurchased $803M stock with $3B buyback authorization.

Bearish Signals

  • Shares fell 5.2% YTD despite earnings beat.
  • GAAP earnings dropped due to share count reductions.
  • Eylea U.S. sales fell 36% amid competition.
  • Bayer collaboration revenues down 17% year over year.
  • Adjusted R&D expenses rose 19% to $1.4 billion.
  • Eylea HD PFS decision delayed beyond April 2026 target.
  • Eylea sales hurt by lower wholesaler inventory.
16
Bullish +75

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

AI-generated analysis

Regeneron Pharmaceuticals announced on May 28, 2026, that the World Health Organization's (WHO) Therapeutics Advisory Group has recommended maftivimab for prioritized evaluation in clinical trials addressing the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda. Maftivimab is the most potent...

Bullish Signals

  • WHO prioritized Regeneron's maftivimab for Bundibugyo ebolavirus trials.
  • Maftivimab is most potent neutralizing antibody with broad Ebola activity.
  • Inmazeb (REGN) was first FDA-approved Ebola treatment with safe profile.
  • Regeneron donated 500 Inmazeb doses to WHO for low-income countries.
  • PALM Trial showed Inmazeb superiority over other treatments in 681 patients.

Bearish Signals

  • Maftivimab lacks in vivo monotherapy data against Bundibugyo ebolavirus.
  • DRC and Uganda trials face potential delays from independent execution.
  • Inmazeb is not approved for Bundibugyo ebolavirus, only Zaire strain.
17
Very Bullish +85

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength

AI-generated analysis

Regeneron Pharmaceuticals reported first-quarter 2026 adjusted earnings per share of $9.47, surpassing the Zacks Consensus Estimate of $8.52 and rising from $8.22 in the year-ago quarter. Total revenues increased 19% year over year to $3.6 billion, driven by higher sales of Eylea HD and expanded...

Bullish Signals

  • Regeneron Q1 2026 EPS hit $9.47, beating estimates by $8.52.
  • Revenue surged 19% YoY to $3.6B on Eylea HD and Dupixent growth.
  • Eylea US revenues reached $468M, up 52% year-over-year.
  • Dupixent sales rose 33% YoY to $4.9B, Sanofi share up 36%.
  • Libtayo generated $438M, up 54% YoY, beating consensus.
  • Regeneron repurchased $803M in stock; $688M remains available.
  • Gross margin improved to 86% from 85% on net product sales.
  • FDA approved Dupixent for pediatric urticaria expansion in April 2026.
  • FDA approved extended Eylea HD dosing up to 20 weeks for wAMD.

Bearish Signals

  • Shares down 5.2% this year vs industry's 1.5% decline.
  • Eylea US sales plunged 36% to $473M amid competition.
  • Sales hurt by lower wholesaler inventory end of Q1 2026.
  • Bayer collaboration revenues fell 17% to $287 million.
  • Second Eylea HD PFS application missed April 2026 target.
  • SG&A rose 4% to $560M, pressuring future profit margins.
  • Operating leverage pressured as Eylea HD faces inventory and competition risks.
18
Bullish +65

Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?

AI-generated analysis

Investors will closely watch Regeneron Pharmaceuticals, Inc. (REGN) as it reports first-quarter 2026 earnings on April 29, 2026, with a primary focus on profits derived from asthma drug Dupixent and sales of Eylea HD. The Zacks Consensus Estimate projects total sales at $3.41 billion and...

Bullish Signals

  • Model predicts earnings beat supported by +5.87% positive Earnings ESP.
  • Dupixent sales jumped 30.8% in Q1 2026 driven by strong demand.
  • Strong Dupixent growth will likely drive incremental Regeneron profits this quarter.
  • Eylea HD initial uptake is strong with US sales pegged at $468M.
  • FDA monthly dosing approval and label expansions boosted Eylea HD sales.
  • Libtayo growth drives top line with non-melanoma demand ($361M estimate).
  • New Libtayo label expansions add upside as adjuvant treatment for CSCC.
  • Otarmeni got accelerated FDA approval as first gene therapy under NVP program.
  • Regeneron authorized $3.0B share repurchase to boost bottom line in Feb 2025.
  • Onco franchise with Libtayo expands revenue base reducing Eylea dependence.

Bearish Signals

  • Eylea sales declined in Q1 due to Vabysmo competition and Eylea HD launch.
  • Regeneron developing Eylea HD highlights weakness in original franchise.
  • Operating expenses increased due to pipeline advancement, new launches, and headcount growth.
  • Company missed earnings estimates one of last four quarters.
  • Libtayo growth depends on label expansions offsetting market pressures.
19
Somewhat Bullish +50

Regeneron reports Pasatru data and Citi holds Regeneron stock

Analyst upgrade Clinical trial results AI-generated analysis

Regeneron Pharmaceuticals reported positive Phase 3 OPTIMA extension data for its drug Pasatru on October 12, 2026. In the 84-week trial involving 63 adults with fibrodysplasia ossificans progressiva, the high-dose treatment resulted in zero new heterotopic ossification lesions compared to nine for placebo. Additionally, only...

Bullish Signals

  • Pasatru trial showed zero new lesions vs nine for placebo in OPTIMA extension.

Bearish Signals

  • Net profit declined to USD 1.30 billion from USD 1.39 billion.
  • Skin infections occurred in 78% of high-dose Pasatru patients.
20
Bullish +55

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

AI-generated analysis

Regeneron Pharmaceuticals (REGN) reported first-quarter 2026 adjusted earnings per share of $9.47, surpassing the Zacks Consensus Estimate of $8.52 and exceeding the prior year's $8.22. Total revenues grew 19% year-over-year to $3.6 billion, driven by strong performance in its key franchises Dupixent and Eylea HD,...

Bullish Signals

  • Adjusted EPS of $9.47 beat consensus estimate of $8.52.
  • Total revenues grew 19% year-over-year to $3.6 billion.
  • Eylea HD generated $468 million U.S. revenue, a 52% increase.
  • Dupixent global sales increased 33% to $4.9 billion.
  • Gross margin improved to 86% from 85%.
  • Executed $803 million share repurchases with $3.0 billion authorization.

Bearish Signals

  • GAAP earnings declined 5.2% vs industry's 1.5% drop.
  • Eylea U.S. sales plunged 36% to $473 million.
  • Eylea HD sales hurt by lower wholesaler inventory.
  • Bayer collaboration revenues decreased 17% to $287M.
  • Praluent net sales only $67 million in U.S.